A5050445670- Ovarian cancer diagnosis and treatment
- Histone Deacetylase Inhibitors Research
- Immunotherapy and Immune Responses
- 14-3-3 protein interactions
- NF-κB Signaling Pathways
- Neuroblastoma Research and Treatments
- Cancer Cells and Metastasis
- Fungal Biology and Applications
- Prostate Cancer Treatment and Research
- Cancer-related molecular mechanisms research
- Cancer Immunotherapy and Biomarkers
- Cancer Mechanisms and Therapy
- Estrogen and related hormone effects
- Cancer, Hypoxia, and Metabolism
- Synthesis and Biological Evaluation
- Plant Molecular Biology Research
- Neuroendocrine Tumor Research Advances
- Immune Cell Function and Interaction
- Cancer-related gene regulation
- Ubiquitin and proteasome pathways
University of Rochester Medical Center
2022-2024
University of Rochester
2023
Epithelial ovarian cancer (EOC) cells seed at mesothelial inflammation or injury sites. Lack of animal models recapitulating tumor seeding inflamed sites in EOC hinders mechanistic studies and therapy developments. Here, we developed a non-surgical MIM (Mesothelium Inflammation/Injury Metastasis) model that recapitulates cell This captures temporal changes immune microenvironment growth allowing for deeper preclinical therapeutic in-vivo. We show here HGS-3 high-grade murine serous...
Small-molecule inhibitors of PD-L1 are postulated to control immune evasion in tumors similar antibodies that target the PD-L1/PD-1 checkpoint axis. However, identity targetable inducers is required develop small-molecule inhibitors. In this study, using chromatin immunoprecipitation (ChIP) assay and siRNA, we demonstrate vitamin D/VDR regulates expression acute myeloid leukemia (AML) myelodysplastic syndrome (MDS) cells. We have examined whether a VDR antagonist, MeTC7, can inhibit PD-L1....
Ovarian cancer is the leading cause of death among gynecologic malignancies. Despite recent advancements in targeted therapies such as PARP inhibitors, recurrence common and frequently resistant to existing therapies. A powerful diagnostic tool, coupled with a comprehensive understanding its implications, crucial. HE4, clinical serum biomarker for ovarian cancer, has shown efficacy monitoring malignant phenotypes, yet little known about biological role regulatory mechanisms. Our research...
Vitamin-D receptor (VDR) mRNA is overexpressed in neuroblastoma and carcinomas of lung, pancreas, ovaries predicts poor prognoses. VDR antagonists may be able to inhibit tumors that overexpress VDR. However, the current are arduous synthesize only partial antagonists, limiting their use. Here, we show antagonist MeTC7 (5), which can synthesized from 7-dehydrocholesterol (6) two steps, inhibits selectively, suppresses viability cancer cell-lines, reduces growth spontaneous transgenic TH-MYCN...
Forchlorfenuron (FCF) is a widely used plant cytokinin that enhances fruit quality and size in agriculture. It also serves as crucial pharmacological tool for the inhibition of septins. However, precise target FCF has not yet been fully determined. This study reveals novel elucidates its downstream signaling events. significantly impairs mitochondrial respiration mediates metabolic shift toward glycolysis, thus making cells more vulnerable to glycolysis inhibition. Interestingly, FCF’s...
e17616 Background: HE4 expression is upregulated in endometrial cancer and has been shown to have prognostic significance patients. High-throughput screening lead optimization led us discover UR-238, a novel small molecule inhibitor of HE4. The purpose this study was investigate the vitro vivo effects UR-238 treatment cancer. Methods: identified by focused medicinal chemistry. Six cell lines (ECC1, AN3CA, HEC1A, MFE296, MFE280, KLE) were grown culture treated with 8 concentrations (125 nM,...